Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "On behalf of the entire Health Robotics' management team, I invite all ASHP attendees to compare and contrast our company's track record now yielding streamlined robotic "live" installations within 60 to 90 days from purchase order; new RFID solutions tracking temperature-controlled I.V. doses from the offsite sterile compounding sites to the hospital pharmacies, on to delivery carts and refrigerated cabinets and all the way to the patient; and finally to witness the new standards in Chemotherapy and Monoclonal Antibody Therapy IV Automation."
Health Robotics will introduce independent and peer-reviewed scientific Oncology Sterile Compounding Automation studies at Health Robotics' customers such as Brigham & Women's Hospital[1], and St. Antonius Hospital[2], which further increases the clear difference between Health Robotics' proven 2nd Generation Oncology robotics technology and that of its competitors'[3]. These Oncology studies show for instance manual versus robotic comparisons in drug potency and patient side effects, $7 per dose direct variable cost savings in consumables, 75% reduction in pharmacist review and approval time, and decreases of 12% to 0.9% in IV errors.
Additionally, since the USA arrival of i.v.STATION ONCO and its adoption by Mercy Hospital in Cedar Rapids and Brigham & Women's Hospital (as a replacement of CytoCare), interested Health-System pharmacists may schedule private ASHP demos or hospital visits for i.v.STATION ONCO or any other Health Robotics solutions by contacting [email protected]. Health Robotics will also be pleased to showcase at Booth 853 multiple European and American Return on Investment customer studies and testimonials for its world-leading solutions i.v.STATION ONCO and i.v.STATION, as well as to schedule private meetings with Health Robotics' executive management team, in advance of the meeting.
----------------------------------
l[1] Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild, 2012: Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs.
l[2] Peters, Capelle, Arvinte, van de Garde, 2012: Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin® (bevacizumab). Remicade® (infliximab) and Herceptin® (trastuzumab).
l[3] Robot Competitors: Loccioni-AEA, IHS-RIVA, MDS-Fresenius, FHT-Baxa-Baxter.